Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough fertility treatment accepted for review

Schering-Plough fertility treatment accepted for review

2nd January 2009

Schering-Plough has announced that its role as a fertility specialist has been strengthened this week after a drug was accepted for review by the European Medicines Agency.

Corifollitropin alfa is a sustained follicle stimulant and is being formulated for use as part of the controlled ovarian stimulation (COS) procedure.

It helps the development of multiple follicles in females who are taking part in an assisted reproductive technology scheme, Schering-Plough explained.

If the treatment is approved following its review, the company’s fertility portfolio would extend and give women more options.

A single dose of corifollitropin alfa would replace seven of a recombinant follicle-stimulating hormone, which women undertake in a COS cycle.

This week’s news release from Schering-Plough is the last for December 2008 ? a month which also saw its combination therapy Pegintron and Rebetol approved for the treatment of paediatric hepatitis C.

The company said this development underlined its commitment to creating more treatment options for those with the disease.

“Thankfully, the number of children with hepatitis C is small, although this chronic infection over time can lead to serious liver disease,” explained Dr Robert J Spiegel, chief medical officer and senior vice-president at the Schering-Plough Research Institute.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.